mind medicine mindmed glp-1 receptor agonist medications The Power of Discovery: Agonists The Impact of GLP-1 Receptor
Description
The Semaglutide Treatment on Coronary Plaque Progression (STOP) trial (NCT03985384) used serial coronary computed tomography angiography (CCTA) to explore the effect of subcutaneous semaglutide on coronary plaque progression in patients with T2DM who had established ASCVD or at least one additional CVD risk factor [113]

Limitations include reliance on small observational studies, lack of randomized controlled trials, heterogeneity across populations, and potential publication bias

"EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens" (Press release)

Muscogiuri G, Verde L, Vetrani C, Barrea L, Savastano S, Colao A

GLP-1 is a target for treatment of diabetes because of the primary peripheral functions of inducing insulin secretion from pancreatic cells, gut emptying and inhibiting glucagon secretion which results in lower blood glucose levels ( GLP-1 can also be produced by neurons in central nervous system (CNS) ( Pathogenesis of AD Amyloid plaque Amyloid beta (A) is a peptide with a molecular weight of 4 KDa and a length of 40-42 amino acids ( 2+ channels and AMPA (-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, to which the neurotransmitter glutamate binds, so A is the most neurotoxic form ( Neurofibrillary tangles Tau is a microtubule-associated protein and mainly found in the axonal compartment ( Synaptic dysfunction and neurotransmitter imbalance It has been well established that cholinergic transmission is essential for memory, learning, attention, and other higher brain functions, so cholinergic deficits play a key role in the neuropathology of AD ( Neuroinflammation Neuroinflammation, microglia activation in response to amyloid deposition, plays a central role in the pathogenesis of AD ( Insulin resistance For the past few years, AD has also been considered as type 3 diabetes because of insulin resistance (IR) and dysregulation of insulin signaling in the brain ( is mainly transported across the BBB

Especially, liraglutide as one the main GLP1-Ras by reducing mean BMI and body weight percentage affects improving WL outcomes
